Patents by Inventor Xiaodong Xiao
Xiaodong Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Method for Preparing Battery-grade Anhydrous Iron Phosphate from Liquid Crude Monoammonium Phosphate
Publication number: 20240101424Abstract: The present invention provides a method for preparing battery-grade anhydrous iron phosphate from liquid crude monoammonium phosphate, and belongs to the technical field of chemical industry production. In the present invention, ferrous sulfate solution and liquid crude monoammonium phosphate are used as raw materials, and ferrous iron is oxidized to ferric iron and separates out iron phosphate precipitate under the action of an oxidizing agent to obtain iron phosphate intermediate slurry; and then battery-grade anhydrous iron phosphate is finally obtained through solid-liquid separation, washing, aging, solid-liquid separation, washing, drying, dehydration and breaking up. The method provided by the present invention realizes the resource utilization of liquid crude monoammonium phosphate, has simple process and convenient operation and produces less waste water.Type: ApplicationFiled: February 21, 2023Publication date: March 28, 2024Applicant: Sichuan UniversityInventors: Xiaodong Guo, Zhenguo Wu, Yang Song, Tongli Liu, Fa He, Meng Xiao -
Patent number: 11912782Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: March 29, 2021Date of Patent: February 27, 2024Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Publication number: 20230331798Abstract: A glycosylation-modified erythropoietin, containing a glycan structure incorporated into an N-glycosylation site, wherein the glycan structure contains FA4G4L2S4.Type: ApplicationFiled: September 18, 2021Publication date: October 19, 2023Inventors: Jianwei ZHU, Hua JIANG, Yueqing XIE, Kaiyong YANG, Xiaodong XIAO, Zhenyu WANG, Man WANG
-
Publication number: 20230201346Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: December 19, 2022Publication date: June 29, 2023Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine ETTINGER, Jodi KARNELL, Melissa DAMSCHRODER, Partha CHOWDHURY, Xiaodong XIAO, Ping TSUI, Reena VARKEY, Stacey DRABIC, Laura CARTER, Ronald HERBST, Qun DU, Brian Michael NAIMAN
-
Publication number: 20230079661Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: ApplicationFiled: August 11, 2022Publication date: March 16, 2023Inventors: Qun WANG, Meghan PENNINI, Xiaodong XIAO, Davide CORTI, Elisabetta CAMERONI, Martina BELTRAMELLO, Gilad KAPLAN, Anna DeMARCO, Charles K. Stover
-
Patent number: 11529415Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: February 5, 2020Date of Patent: December 20, 2022Assignee: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 11447542Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: August 4, 2017Date of Patent: September 20, 2022Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Qun Wang, Charles K. Stover, Meghan Pennini, Xiaodong Xiao, Davide Corti, Elisabetta Cameroni, Martina Beltramello, Gilad Kaplan, Anna DeMarco
-
Publication number: 20220056113Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: ApplicationFiled: August 9, 2021Publication date: February 24, 2022Inventors: Qun WANG, Charles K. STOVER, Meghan PENNINI, Chew-shun CHANG, Xiaodong XIAO, Jamese HILLIARD, Gilad KAPLAN, Davide CORTI, Elisabetta CAMERONI, Martina BELTRAMELLO
-
Patent number: 11117956Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: October 16, 2017Date of Patent: September 14, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Qun Wang, Charles Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello
-
Publication number: 20210238263Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: ApplicationFiled: August 4, 2017Publication date: August 5, 2021Inventors: Qun Wang, Charles K. Stover, Meghan Pennini, Xiaodong Xiao, Davide Corti, Elisabetta Cameroni, Martina Beltramello, Gilad KAPLAN, Anna DeMARCO
-
Publication number: 20210214460Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: ApplicationFiled: March 29, 2021Publication date: July 15, 2021Inventors: Krista KINNEER, Reena VARKEY, Xiaodong XIAO, Elaine M. HURT, David TICE
-
Patent number: 10988546Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: July 31, 2018Date of Patent: April 27, 2021Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Publication number: 20200231660Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: ApplicationFiled: October 16, 2017Publication date: July 23, 2020Inventors: Qun Wang, Charles Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello
-
Publication number: 20200164069Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: ApplicationFiled: February 5, 2020Publication date: May 28, 2020Applicant: Boston Pharmaceuticals Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10588969Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.Type: GrantFiled: June 11, 2018Date of Patent: March 17, 2020Assignee: Boston Pharmaceuticals, Inc.Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
-
Patent number: 10494435Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: GrantFiled: February 3, 2017Date of Patent: December 3, 2019Assignee: The Government of the United States America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Publication number: 20190352425Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.Type: ApplicationFiled: June 6, 2019Publication date: November 21, 2019Inventors: Chien-Ying CHANG, Xiaodong XIAO, Partha CHOWDHURY
-
Patent number: 10351630Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.Type: GrantFiled: January 8, 2016Date of Patent: July 16, 2019Assignee: MEDIMMUNE, LLCInventors: Chien-Ying Chang, Xiaodong Xiao, Partha Chowdhury
-
Publication number: 20190062411Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.Type: ApplicationFiled: March 29, 2018Publication date: February 28, 2019Applicant: MedImmune, LLCInventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu LIN
-
Publication number: 20190040152Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: ApplicationFiled: July 31, 2018Publication date: February 7, 2019Inventors: Krista KINNEER, Reena VARKEY, Xiaodong XIAO, Elaine M. HURT, David TICE